83 related articles for article (PubMed ID: 17191171)
21. Immunomodulatory activities of IFN-gamma1b in combination with type I IFN: implications for the use of IFN-gamma1b in the treatment of chronic HCV infections.
Wang T; Blatt LM; Seiwert SD
J Interferon Cytokine Res; 2006 Jul; 26(7):473-83. PubMed ID: 16800786
[TBL] [Abstract][Full Text] [Related]
22. A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone.
Fattovich G; Zagni I; Ribero ML; Castagnetti E; Minola E; Lomonaco L; Scattolini C; Fabris P; Boccia S; Giusti M; Abbati G; Felder M; Rovere P; Redaelli A; Tonon A; Tomba A; Montanari R; Paternoster C; Distasi M; Fornaciari G; Tositti G; Rizzo C; Suppressa S; Pantalena M; Noventa F; Tagger A
J Viral Hepat; 2004 Nov; 11(6):543-51. PubMed ID: 15500555
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
24. Treatment of chronic hepatitis C in southern Taiwan.
Chuang WL; Yu ML; Dai CY; Chang WY
Intervirology; 2006; 49(1-2):99-106. PubMed ID: 16166797
[TBL] [Abstract][Full Text] [Related]
25. Changes in TNF-alpha mRNA levels in the peripheral blood of patients with chronic hepatitis C virus (HCV) infection during alpha-interferon and ribavirin therapy.
Sypniewski D; Jurzak M; Cholewa K; Gola J; Mazurek U; Wilczok T; Rozek-Kostórkiewicz J; Mazur W; Gonciarz Z
Viral Immunol; 2004; 17(4):580-7. PubMed ID: 15671755
[TBL] [Abstract][Full Text] [Related]
26. HCV Infection and Interferon-Based Treatment Induce p53 Gene Transcription in Chronic Hepatitis C Patients.
Świątek-Kościelna B; Kałużna EM; Januszkiewicz-Lewandowska D; Rembowska J; Mozer-Lisewska I; Bereszyńska I; Czubała K; Dziechciowska K; Wysocka-Leszczyńska J; Barcińska D; Wysocki J; Nowak JS
Viral Immunol; 2015 Oct; 28(8):434-41. PubMed ID: 26266944
[TBL] [Abstract][Full Text] [Related]
27. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
[TBL] [Abstract][Full Text] [Related]
28. Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C.
Murata K; Yamamoto N; Kawakita T; Saito Y; Yamanaka Y; Sugimoto K; Shiraki K; Nakano T; Tameda Y
Hepatogastroenterology; 2005; 52(62):547-51. PubMed ID: 15816475
[TBL] [Abstract][Full Text] [Related]
29. Treatment of hepatitis C virus infection in patients of northern India.
Hazari S; Panda SK; Gupta SD; Batra Y; Singh R; Acharya SK
J Gastroenterol Hepatol; 2004 Sep; 19(9):1058-65. PubMed ID: 15304125
[TBL] [Abstract][Full Text] [Related]
30. [Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C].
Lee HJ; Eun JR; Choi JW; Kim KO; Moon HJ
Korean J Hepatol; 2008 Mar; 14(1):46-57. PubMed ID: 18367857
[TBL] [Abstract][Full Text] [Related]
31. A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load.
Izumi N; Asahina Y; Kurosaki M; Uchihara M; Nishimura Y; Inoue K; Ueda K; Tsuchiya K; Hamano K; Itakura J; Miyake S
Intervirology; 2004; 47(2):102-7. PubMed ID: 15192274
[TBL] [Abstract][Full Text] [Related]
32. Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.
Ballesteros AL; Miró O; López S; Fuster D; Videla S; Martínez E; Garrabou G; Salas A; Côté H; Tor J; Rey-Joly C; Planas R; Clotet B; Tural C
Antivir Ther; 2004 Dec; 9(6):969-77. PubMed ID: 15651755
[TBL] [Abstract][Full Text] [Related]
33. [Changes of immunocytes in livers of chronic hepatitis C patients treated with IFN alpha-2b and ribavirin].
Yang XH; Liu BR; Jiang HC; Li SC
Zhonghua Gan Zang Bing Za Zhi; 2006 Dec; 14(12):884-6. PubMed ID: 17196128
[TBL] [Abstract][Full Text] [Related]
34. Effects of ribavirin combined with interferon-alpha 2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads.
Enomoto M; Nishiguchi S; Kohmoto M; Tamori A; Habu D; Takeda T; Seki S; Shiomi S
J Viral Hepat; 2004 Sep; 11(5):448-54. PubMed ID: 15357651
[TBL] [Abstract][Full Text] [Related]
35. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
[TBL] [Abstract][Full Text] [Related]
36. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
37. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis.
Sporea I; Danila M; Sirli R; Popescu A; Laza A; Baditoiu L
J Gastrointestin Liver Dis; 2006 Jun; 15(2):125-30. PubMed ID: 16802006
[TBL] [Abstract][Full Text] [Related]
38. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.
Aghemo A; Rumi MG; Soffredini R; D'Ambrosio R; Ronchi G; Del Ninno E; Gallus S; Colombo M
Antivir Ther; 2006; 11(6):797-802. PubMed ID: 17310824
[TBL] [Abstract][Full Text] [Related]
39. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
40. Undetectable phospho-STAT1 in peripheral blood mononuclear cells from patients with chronic hepatitis C who do not respond to interferon-alpha therapy.
Aceti A; Zechini B; Griggi T; Marangi M; Pasquazzi C; Quaranta G; Sorice M
Liver Int; 2005 Oct; 25(5):987-93. PubMed ID: 16162158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]